Last reviewed · How we verify

NCT07430293: HCL PP

Hybrid Closed-Loop Insulin Delivery After Pancreatectomy

Not yet recruiting NA Last updated 24 February 2026
What this trial tests

NA trial testing MiniMed 780 associated with Simplera in Pancreatectomy in 24 participants. Not yet recruiting.

Timeline
1 March 2026
Primary endpoint
1 September 2027
1 September 2027

Quick facts

Lead sponsorCentre Hospitalier Sud Francilien
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment24
Start date1 March 2026
Primary completion1 September 2027
Estimated completion1 September 2027
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Sud Francilien

Who can join

18 and older, any sex, with Pancreatectomy or Total Pancreatectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Individuals with diabetes secondary to pancreatectomy experience impaired quality of life, partly due to the challenges of managing highly variable blood glucose levels. Hybrid closed-loop (HCL) automated insulin delivery (AID) systems, widely evaluated in type 1 diabetes, may improve both metabolic outcomes and quality of life in this population. A review of the literature identified a few observational studies reporting promising results with HCL systems in the context of post-pancreatectomy diabetes. Only one randomized trial has evaluated AID in this population, showing excellent outcomes, but using a complex bihormonal system that is not yet commercially available worldwide. Consequently, there remains a lack of confirmatory evidence regarding the efficacy of commercially available monohormonal HCL systems in individuals with diabetes secondary to pancreatectomy, evidence that is crucial to support broader access to this technology. The intervention will consist in a 3-month AID treatment combining MiniMed 780 and Simplera. The control period will consist in 3 months using the Simplera for continuous glucose monitoring, alongside participant usual diabetes treatment. The primary outcome is the percentage of time that interstitial glucose levels remain within the target range (70-180 mg/dL), as measured by continuous glucose monitoring (CGM, Simplera), over a 3-month period using the MiniMed 780 hybrid closed-loop system, compared to a 3-month period under the participant's usual diabetes treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pancreatectomy

Currently open trials in the same condition.

Other Centre Hospitalier Sud Francilien trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07430293.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing